Advanced search
Publication Cover
Immunopharmacology and Immunotoxicology Volume 43, 2021 - Issue 3
Submit an article Journal homepage
2,631
Views
13
CrossRef citations to date
0
Altmetric
Reviews

Anti-IgE monoclonal antibodies as potential treatment in COVID-19

Ahmad Reza Farmania Tissue Engineering and Applied Cell Sciences Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran;b Tissue Engineering Department, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran;c Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0003-1149-3843
ORCID Icon,
Forough Mahdavinezhadd Anatomy Department-School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
,
Rohollah Moslemie Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
,
Zeinab Mehrabif Internal Medicine Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
,
Alireza Nooria Tissue Engineering and Applied Cell Sciences Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
,
Mahsa Kouhestania Tissue Engineering and Applied Cell Sciences Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
,
Zahra Noroozig Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
,
Jafar Aia Tissue Engineering and Applied Cell Sciences Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
&
Nima Rezaeih Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran;i Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;j Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, IranCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3836-1827
ORCID Icon show all
Pages 259-264 | Received 30 Dec 2020, Accepted 29 Apr 2021, Published online: 21 May 2021

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Negin Farhadian, Maryam Farhadian, Mohammad Hossein Zamanian, Mahdi Taghadosi & Siavash Vaziri. (2023) Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis. Immunopharmacology and Immunotoxicology 45:4, pages 402-408.
Read now
Jingjing Zhang, Han Zhang & Litao Sun. (2022) Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. mAbs 14:1.
Read now
Dimitri Poddighe & Elena Kovzel. (2021) Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome. Journal of Inflammation Research 14, pages 6845-6853.
Read now

Articles from other publishers (10)

Daniele Giovanni Ghiglioni, Laura Cozzi, Riccardo Castagnoli, Gaia Bruschi, Laura Maffeis, Paola Giovanna Marchisio, Gian Luigi Marseglia & Amelia Licari. (2023) Omalizumab may protect allergic patients against COVID-19: A systematic review. World Allergy Organization Journal 16:2, pages 100741.
Crossref
Öner Özdemir & Ümmügülsüm Dikici. (2022) Safely use of omalizumab during SARS‐CoV ‐2 infection in patients with chronic spontaneous urticaria . Journal of Cosmetic Dermatology 22:1, pages 26-27.
Crossref
Jānis Plūme, Artis Galvanovskis, Sindija Šmite, Nadezhda Romanchikova, Pawel Zayakin & Aija Linē. (2022) Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients. Journal of Translational Medicine 20:1.
Crossref
Hadi Zare MarzouniMarjan RahbarNazanin SeddighiMohsen NabizadehSepideh MeidaninikjehNasim Sabouni. (2022) Antibody Therapy for COVID-19: Categories, Pros, and Cons. Viral Immunology 35:8, pages 517-528.
Crossref
Ahmad Reza Farmani, Mohammad Ali Salmeh, Zahra Golkar, Alaa Moeinzadeh, Farzaneh Farid Ghiasi, Sara Zamani Amirabad, Mohammad Hasan Shoormeij, Forough Mahdavinezhad, Simin Momeni, Fatemeh Moradbeygi, Jafar Ai, John G. Hardy & Amir Mostafaei. (2022) Li-Doped Bioactive Ceramics: Promising Biomaterials for Tissue Engineering and Regenerative Medicine. Journal of Functional Biomaterials 13:4, pages 162.
Crossref
Ahmad Reza Farmani, Forough Mahdavinezhad, Carolina Scagnolari, Mahsa Kouhestani, Sadegh Mohammadi, Jafar Ai, Mohammad Hasan Shoormeij & Nima Rezaei. (2021) An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19. Drug Delivery and Translational Research 12:7, pages 1605-1615.
Crossref
Michal Podrazil, Pavla Taborska, Dmitry Stakheev, Michal Rataj, Jan Lastovicka, Alena Vlachova, Petr Pohunek, Jirina Bartunkova & Daniel Smrz. (2022) Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. Frontiers in Immunology 13.
Crossref
Abrahim Abduelmula, Jorge R. Georgakopoulos, Asfandyar Mufti, Alim R. Devani, Melinda J. Gooderham, Chih-Ho Hong, Vipul Jain, Perla Lansang, Ronald Vender, Vimal H. Prajapati & Jensen Yeung. (2021) Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. Journal of Cutaneous Medicine and Surgery 26:3, pages 319-320.
Crossref
Carlos H. Hiroki, Nicole Sarden, Mortaza F. Hassanabad & Bryan G. Yipp. (2021) Innate Receptors Expression by Lung Nociceptors: Impact on COVID-19 and Aging. Frontiers in Immunology 12.
Crossref
Ecem Bostan, Fethi Zaid, Aysen Karaduman, Sibel Dogan, Duygu Gulseren, Basak Yalici‐Armagan, Neslihan Akdogan, Sibel Ersoy‐Evans & Gonca Elcin. (2021) The effect of COVID‐19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross‐sectional, comparative study. Journal of Cosmetic Dermatology 20:11, pages 3369-3375.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.